Growth hormone (GH) replacement therapy increased left ventricular (LV) mass and improved metabolic parameters in prepubertal children with growth hormone deficiency (GHD), according to a study from Spain.
Long-term treatment with subcutaneous (SC) abatacept (ABA) is safe, tolerable and effective in patients with rheumatoid arthritis (RA) who are refractory to methotrexate (MTX), according to 5-year data from a recent study.
The combination of dolutegravir + lamivudine appeared noninferior to dolutegravir + tenofovir/emtricitabine in reducing viral load in treatment-naïve patients with HIV-1 infection, according to the phase III GEMINI-1 and GEMINI-2* trials presented at AIDS 2018.
Simplification from combination antiretroviral therapy (cART) to dolutegravir monotherapy as maintenance treatment was noninferior to continuing therapy with cART, at least in patients who initiated cART during primary HIV infection and had achieved suppressed viral load for ≥48 weeks, suggests a study presented at IAC 2018.
The dual bronchodilator indacaterol/glycopyrronium (IND/GLY) is highly cost-effective compared to the inhaled corticosteroid-containing salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are a low risk of exacerbation in the Singapore healthcare setting, suggests a study.
Selective inhibition of Janus kinase 1 with upadacitinib shows promise in the treatment of rheumatoid arthritis patients with inadequate response to biologic or conventional synthetic disease-modifying antirheumatic drugs, according to data from two phase III trials.
The use of the sustained-release, recombinant human growth hormone (rhGH) LB03002 given once a week may be an alternative to immediate-release, daily rhGH in increasing the height of prepubertal children with idiopathic short stature, according to a phase II study from Korea.
The use of the investigational selective Janus kinase 1 (JAK1) inhibitor upadacitinib, either alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), led to rapid and significant clinical improvements in patients with moderate-to-severe rheumatoid arthritis (RA), including those who had been refractory to biologic DMARDs (bDMARDs), according to two multicentre phase III trials.
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
New drug applications approved by US FDA as of 16 - 31 May 2017 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.